CCHT(SZ:000661)2022-12-07 08:46Group 1: Company Direction and Strategy - The company maintains its focus on biopharmaceuticals and related industries, asserting that its core business direction will not change despite winning a real estate project worth over 10 billion [3] - The company emphasizes two unwavering commitments: maintaining its primary business in biopharmaceuticals and pursuing innovation as a growth strategy [3] Group 2: Subsidiary and Market Engagement - The company is open to utilizing multi-tiered capital markets for the development of its subsidiaries while ensuring it retains control over them [4] - The company is closely monitoring the development of multi-tiered capital markets and studying relevant cases [4] Group 3: Product Development and Investment - The company plans to allocate 800 million for new product research and development from the proceeds of its fundraising [5] - New product development includes a range of projects such as assisted reproductive products, original monoclonal antibodies for cancer and inflammation, and vaccines for various diseases [6]